Advisors Preferred’s Meridian Bioscience Inc VIVO Stock Holding History

Advisors Preferred’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-15,560	Closed	-$274K	–	305
2019 Q1	$274K	Buy	15,560 +9,479	+156%	+$158K	0.09%	78
2018 Q4	$106K	Buy	+6,081	New	+$104K	0.13%	68
2018 Q2	–	Sell	-4,603	Closed	-$65K	–	302
2018 Q1	$65K	Buy	+4,603	New	+$68.1K	0.03%	157

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Preferred's VIVO Position: Q2 2019 in Review

Advisors Preferred sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 15,560 shares — an estimated $274K sold.

Advisors Preferred first reported a position in VIVO in Q1 2018 and held it in 3 quarters. The position peaked at $274K in Q1 2019. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

Advisors Preferred reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
Advisors Preferred sold 15,560 Meridian Bioscience Inc shares in Q2 2019, an estimated $274K.
Advisors Preferred first reported a position in Meridian Bioscience Inc in Q1 2018 and held it in 3 quarters.
Advisors Preferred's Meridian Bioscience Inc position peaked at $274K in Q1 2019.
173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on Advisors Preferred's 13F filing for Q2 2019, filed 6 Aug 2019.